{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:11:59Z","timestamp":1789560719990,"version":"build-2803163510"},"reference-count":213,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016714","name":"University of Sharjah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Genetic Engineering and Biotechnology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jgeb.2026.100717","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:16:59Z","timestamp":1780618619000},"page":"100717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges"],"prefix":"10.1016","volume":"24","author":[{"given":"Iman","family":"Wehbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelaziz","family":"Tlili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.jgeb.2026.100717_bb0005","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.3390\/ijms21134569","article-title":"Genetic markers in lung Cancer diagnosis: a review","volume":"21","author":"Wadowska","year":"2020","journal-title":"IJMS"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CM9.0000000000001802","article-title":"Primary tumor location in lung cancer: the evaluation and administration","volume":"135","author":"Xie","year":"2022","journal-title":"Chin Med J"},{"key":"10.1016\/j.jgeb.2026.100717_bb0015","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.jgeb.2026.100717_bb0020","doi-asserted-by":"crossref","unstructured":"Chaitanya Thandra K, Barsouk A, Saginala K, Sukumar Aluru J, Barsouk A. Epidemiology of lung cancer wo 2021;25(1):45\u201352. doi:https:\/\/doi.org\/10.5114\/wo.2021.103829, Wspolczesna Onkol.","DOI":"10.5114\/wo.2021.103829"},{"issue":"9","key":"10.1016\/j.jgeb.2026.100717_bb0025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jgeb.2026.100717_bb0030","series-title":"StatPearls","article-title":"Lung Cancer","author":"Siddiqui","year":"2025"},{"key":"10.1016\/j.jgeb.2026.100717_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102693","article-title":"Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN","volume":"93","author":"Zhou","year":"2024","journal-title":"Cancer Epidemiol"},{"issue":"15","key":"10.1016\/j.jgeb.2026.100717_bb0040","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.3390\/cancers15153980","article-title":"Targeting cell Signaling pathways in lung Cancer by bioactive phytocompounds","volume":"15","author":"Choudhary","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.jgeb.2026.100717_bb0045","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3390\/cells10081879","article-title":"Role of NRF2 in lung Cancer","volume":"10","author":"S\u00e1nchez-Ortega","year":"2021","journal-title":"Cells"},{"issue":"15","key":"10.1016\/j.jgeb.2026.100717_bb0050","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.3390\/cancers13153711","article-title":"The role of surgery in lung Cancer treatment: present indications and future perspectives\u2014state of the art","volume":"13","author":"Montagne","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jgeb.2026.100717_bb0055","first-page":"S479","article-title":"Molecular biology of lung cancer","volume":"5 Suppl 5(Suppl 5)","author":"Cooper","year":"2013","journal-title":"J Thorac Dis"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0060","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/jcm14031025","article-title":"NSCLC: current evidence on its pathogenesis, integrated treatment, and future perspectives","volume":"14","author":"Tahayneh","year":"2025","journal-title":"JCM"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0065","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00262-021-03013-3","article-title":"Chemotherapy: a double-edged sword in cancer treatment","volume":"71","author":"Behranvand","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","article-title":"Molecular mechanisms of tumor resistance to radiotherapy","volume":"22","author":"Wu","year":"2023","journal-title":"Mol Cancer"},{"issue":"29","key":"10.1016\/j.jgeb.2026.100717_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202417571","article-title":"Recent advances in mRNA delivery systems for cancer therapy","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv Sci"},{"key":"10.1016\/j.jgeb.2026.100717_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108999","article-title":"TTYH3, a potential prognosis biomarker associated with immune infiltration and immunotherapy response in lung cancer","volume":"110","author":"Wei","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"4776","key":"10.1016\/j.jgeb.2026.100717_bb0090","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/190576a0","article-title":"An unstable intermediate carrying information FROMGENES to ribosomes for protein synthesis","volume":"190","author":"Brenner","year":"1961","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0095","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Sig Transduct Target Ther"},{"issue":"4949","key":"10.1016\/j.jgeb.2026.100717_bb0100","first-page":"1465","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science (1979)"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI0214364","article-title":"Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors","volume":"109","author":"Heiser","year":"2002","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.jgeb.2026.100717_bb0110","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.jgeb.2026.100717_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.102013","article-title":"Delivery of mRNA for cancer therapy: progress and prospects","volume":"53","author":"Su","year":"2023","journal-title":"Nano Today"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0120","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s42003-021-02470-x","article-title":"Mapping lung squamous cell carcinoma pathogenesis through in vitro and in vivo models","volume":"4","author":"G\u00f3mez-L\u00f3pez","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.jgeb.2026.100717_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111450","article-title":"The metastasizing mechanisms of lung cancer: recent advances and therapeutic challenges","volume":"138","author":"Xie","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.jgeb.2026.100717_bb0130","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ccm.2011.08.003","article-title":"Molecular biology of lung Cancer: clinical implications","volume":"32","author":"Larsen","year":"2011","journal-title":"Clin Chest Med"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0135","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/cells10010046","article-title":"Tumor suppressors having oncogenic functions: the double agents","volume":"10","author":"Datta","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.jgeb.2026.100717_bb0140","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/1947-2714.157476","article-title":"Tumor-suppressor genes, cell cycle regulatory checkpoints, and the skin","volume":"7","author":"Velez","year":"2015","journal-title":"North Am J Med Sci"},{"key":"10.1016\/j.jgeb.2026.100717_bb0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.21037\/pcm-20-72","article-title":"Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review","volume":"4","author":"Bruno","year":"2021","journal-title":"Precis Cancer Med"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/ejop.ejop_33_18","article-title":"Molecular genetics of lung cancer","volume":"20","author":"Cicek","year":"2018","journal-title":"Eurasian J Pulmonol"},{"issue":"9","key":"10.1016\/j.jgeb.2026.100717_bb0155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0160","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000323874","article-title":"Epigenetics: principles and practice","volume":"29","author":"Hamilton","year":"2011","journal-title":"Dig Dis"},{"issue":"6","key":"10.1016\/j.jgeb.2026.100717_bb0165","article-title":"Epigenetic regulation in lung cancer","volume":"4","author":"Ramazi","year":"2023","journal-title":"MedComm (Beijing)"},{"issue":"6","key":"10.1016\/j.jgeb.2026.100717_bb0170","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3390\/cells12060905","article-title":"A systematic review of Progress toward unlocking the power of epigenetics in NSCLC: latest updates and perspectives","volume":"12","author":"Sulewska","year":"2023","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.jgeb.2026.100717_bb0175","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.3390\/cancers15102709","article-title":"Intratumoral heterogeneity in lung Cancer","volume":"15","author":"Lv","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.jgeb.2026.100717_bb0180","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.21037\/tlcr-2025-506","article-title":"A narrative review of imaging intratumor heterogeneity in non-small cell lung cancer: current advances","volume":"14","author":"Lin","year":"2025","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"10.1016\/j.jgeb.2026.100717_bb0185","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","article-title":"Intratumor and Intertumor heterogeneity in melanoma","volume":"10","author":"Grzywa","year":"2017","journal-title":"Transl Oncol"},{"issue":"7","key":"10.1016\/j.jgeb.2026.100717_bb0190","doi-asserted-by":"crossref","first-page":"981","DOI":"10.7150\/ijms.34739","article-title":"Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications","volume":"16","author":"Marino","year":"2019","journal-title":"Int J Med Sci"},{"issue":"23","key":"10.1016\/j.jgeb.2026.100717_bb0195","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3390\/cancers16233892","article-title":"Intratumoral treatment in lung Cancer: is it time to move towards clinical practice?","volume":"16","author":"Pagliari","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0200","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12935-025-03734-w","article-title":"Intratumoral heterogeneity and drug resistance in cancer","volume":"25","author":"Fu","year":"2025","journal-title":"Cancer Cell Int"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0205","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jgeb.2026.100717_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108586","article-title":"Targeting CAFs and extracellular matrix (ECM) in lung cancer: potential of adjuvants and nanoparticles","volume":"162","author":"Feng","year":"2025","journal-title":"Bioorg Chem"},{"issue":"5","key":"10.1016\/j.jgeb.2026.100717_bb0215","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3892\/ol.2021.12674","article-title":"Role of cancer-associated fibroblasts in the resistance to antitumor therapy, and their potential therapeutic mechanisms in non-small cell lung cancer (review)","volume":"21","author":"Chen","year":"2021","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0220","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s42003-022-04350-4","article-title":"An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer","volume":"6","author":"Lobb","year":"2023","journal-title":"Commun Biol"},{"issue":"16","key":"10.1016\/j.jgeb.2026.100717_bb0225","doi-asserted-by":"crossref","first-page":"8899","DOI":"10.3390\/ijms25168899","article-title":"Cracking the codes behind Cancer cells\u2019 immune evasion","volume":"25","author":"Mundhara","year":"2024","journal-title":"IJMS"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0230","doi-asserted-by":"crossref","first-page":"382","DOI":"10.21037\/jtd.2019.01.22","article-title":"Understanding the mechanisms of immune-evasion by lung cancer in the context of chronic inflammation in emphysema","volume":"11","author":"Salehi-Rad","year":"2019","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jgeb.2026.100717_bb0235","article-title":"Mechanisms of angiogenesis in tumour","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.jgeb.2026.100717_bb0240","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jgeb.2026.100717_bb0245","first-page":"S425","article-title":"Lung cancer surgery: an up to date","author":"Baltayiannis","year":"2013","journal-title":"J Thorac Dis"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0250","article-title":"The survival advantage of lobectomy over wedge resection lessens as health-related life expectancy decreases","volume":"2","author":"Salazar","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0255","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejcsup.2013.07.021","article-title":"Surgical treatment of early-stage non-small-cell lung cancer","volume":"11","author":"Van Schil","year":"2013","journal-title":"Eur J Cancer Suppl"},{"issue":"6","key":"10.1016\/j.jgeb.2026.100717_bb0260","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.4240\/wjgs.v15.i6.1056","article-title":"Surgical complications of oncological treatments: a narrative review","volume":"15","author":"Fico","year":"2023","journal-title":"World J Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0265","doi-asserted-by":"crossref","DOI":"10.5935\/0103-507X.20160012","article-title":"Postoperative complications and clinical outcomes among patients undergoing thoracic and gastrointestinal cancer surgery: a prospective cohort study","volume":"28","author":"Martos-Ben\u00edtez","year":"2016","journal-title":"Rev Bras Ter Intensiva"},{"issue":"2\u20133","key":"10.1016\/j.jgeb.2026.100717_bb0270","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/02841860151116204","article-title":"What is cancer chemotherapy?","volume":"40","author":"Nygren","year":"2001","journal-title":"Acta Oncol (Madr)"},{"issue":"5","key":"10.1016\/j.jgeb.2026.100717_bb0275","doi-asserted-by":"crossref","DOI":"10.19080\/OAJT.2018.02.555600","article-title":"Chemotherapy treatment and strategy schemes: a review","volume":"2","author":"Alam","year":"2018","journal-title":"OAJT"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0280","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0377-1237(10)80132-7","article-title":"Radiotherapy: basic concepts and recent advances","volume":"66","author":"Mehta","year":"2010","journal-title":"Med J Armed Forces India"},{"key":"10.1016\/j.jgeb.2026.100717_bb0285","article-title":"Review: mechanisms and perspective treatment of radioresistance in non-small cell lung cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jgeb.2026.100717_bb0290","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3892\/ijo.2014.2614","article-title":"Radiation-induced signaling pathways that promote cancer cell survival (review)","volume":"45","author":"Hein","year":"2014","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jgeb.2026.100717_bb0295","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2147\/CMAR.S351744","article-title":"Technological advancements in external beam radiation therapy (EBRT): an indispensable tool for Cancer treatment","volume":"14","author":"Koka","year":"2022","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0300","doi-asserted-by":"crossref","first-page":"20220992","DOI":"10.1515\/biol-2022-0992","article-title":"Myriad factors and pathways influencing tumor radiotherapy resistance","volume":"19","author":"Mi","year":"2024","journal-title":"Open Life Sci"},{"issue":"10","key":"10.1016\/j.jgeb.2026.100717_bb0305","article-title":"Mechanisms of radiation-induced tissue damage and response","volume":"5","author":"Zhou","year":"2024","journal-title":"MedComm (Beijing)"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0310","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.jgeb.2026.100717_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1366260","article-title":"Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges","author":"Xiang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jgeb.2026.100717_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2024.100860","article-title":"Personalized medicine: an alternative for cancer treatment","volume":"42","author":"Singh","year":"2024","journal-title":"Cancer Treatment and Research Communications"},{"issue":"12","key":"10.1016\/j.jgeb.2026.100717_bb0325","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.3390\/biomedicines12122750","article-title":"Revolutionizing personalized medicine: synergy with multi-omics data generation, Main hurdles, and future perspectives","volume":"12","author":"Molla","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jgeb.2026.100717_bb0330","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fphar.2019.00230","article-title":"Advances in targeted therapy and immunotherapy for non-small cell lung Cancer based on accurate molecular typing","volume":"10","author":"Dong","year":"2019","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.jgeb.2026.100717_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12092158","article-title":"Revolutionizing cancer treatment: recent advances in immunotherapy","volume":"12","author":"Ghemrawi","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jgeb.2026.100717_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106921","article-title":"Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non-small cell lung cancer","volume":"196","author":"Guo","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jgeb.2026.100717_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1489977","article-title":"Biomarkers for immunotherapy resistance in non-small cell lung cancer","volume":"14","author":"Rother","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13010099","article-title":"Radiotherapy, chemotherapy and immunotherapy\u2014current practice and future perspectives for recurrent\/metastatic oral cavity squamous cell carcinoma","volume":"13","author":"Melo-Alvim","year":"2022","journal-title":"Diagnostics"},{"issue":"37","key":"10.1016\/j.jgeb.2026.100717_bb0355","doi-asserted-by":"crossref","first-page":"62742","DOI":"10.18632\/oncotarget.18409","article-title":"Improving radiotherapy in cancer treatment: promises and challenges","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jgeb.2026.100717_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102277","article-title":"Impact of radiotherapy on secondary lung cancer risk and survival in elderly female breast cancer survivors","volume":"52","author":"Lu","year":"2025","journal-title":"Transl Oncol"},{"issue":"10","key":"10.1016\/j.jgeb.2026.100717_bb0365","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp Mol Med"},{"issue":"23","key":"10.1016\/j.jgeb.2026.100717_bb0370","article-title":"The RNA revolution in the central molecular biology dogma evolution","volume":"25","author":"Haseltine","year":"2024","journal-title":"IJMS"},{"key":"10.1016\/j.jgeb.2026.100717_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2012.00439","article-title":"Is central dogma a global property of cellular information flow?","author":"Piras","year":"2012","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0380","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Sig Transduct Target Ther"},{"issue":"44","key":"10.1016\/j.jgeb.2026.100717_bb0385","doi-asserted-by":"crossref","first-page":"15795","DOI":"10.1021\/acs.nanolett.5c03826","article-title":"Advancing lung Cancer treatment: mRNA therapeutics and delivery strategies","volume":"25","author":"Yaremenko","year":"2025","journal-title":"Nano Lett"},{"issue":"10","key":"10.1016\/j.jgeb.2026.100717_bb0390","doi-asserted-by":"crossref","first-page":"9015","DOI":"10.1007\/s12274-024-6978-6","article-title":"mRNA medicine: recent progresses in chemical modification, design, and engineering","volume":"17","author":"Hou","year":"2024","journal-title":"Nano Res"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0395","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J Biomed Sci"},{"issue":"8","key":"10.1016\/j.jgeb.2026.100717_bb0400","article-title":"The delivery of mRNA vaccines for therapeutics","volume":"12","author":"Nitika","year":"2022","journal-title":"Life (Basel)"},{"issue":"8","key":"10.1016\/j.jgeb.2026.100717_bb0405","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1021\/acs.molpharmaceut.4c00276","article-title":"Advancing mRNA therapeutics: the role and future of nanoparticle delivery systems","volume":"21","author":"Li","year":"2024","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0410","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/acsnanoscienceau.2c00062","article-title":"Recent advances in site-specific lipid nanoparticles for mRNA delivery","volume":"3","author":"Xu","year":"2023","journal-title":"ACS Nanosci Au"},{"issue":"6","key":"10.1016\/j.jgeb.2026.100717_bb0415","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1021\/acs.nanolett.2c04486","article-title":"Engineered Design of a Mesoporous Silica Nanoparticle-Based Nanocarrier for efficient mRNA delivery in vivo","volume":"23","author":"Dong","year":"2023","journal-title":"Nano Lett"},{"key":"10.1016\/j.jgeb.2026.100717_bb0420","article-title":"Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0425","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/vaccines9010065","article-title":"Nanomaterial delivery systems for mRNA vaccines","volume":"9","author":"Buschmann","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1016\/j.jgeb.2026.100717_bb0430","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat Rev Genet"},{"issue":"20","key":"10.1016\/j.jgeb.2026.100717_bb0435","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/acs.accounts.5c00522","article-title":"Ionizable lipid nanoparticles for mRNA delivery: internal self-assembled inverse mesophase structure and endosomal escape","volume":"58","author":"Yu","year":"2025","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.jgeb.2026.100717_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0445","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11030-023-10648-0","article-title":"Identification of 5-nitroindazole as a multitargeted inhibitor for CDK and transferase kinase in lung cancer: a multisampling algorithm-based structural study","volume":"28","author":"Ahmad","year":"2024","journal-title":"Mol Divers"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0450","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2024.5669","article-title":"mRNA vaccine development and applications: a special focus on tumors (review)","volume":"65","author":"Chen","year":"2024","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0455","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/wrna.40","article-title":"Mechanisms of deadenylation-dependent decay","volume":"2","author":"Chen","year":"2011","journal-title":"WIREs RNA"},{"issue":"19","key":"10.1016\/j.jgeb.2026.100717_bb0460","article-title":"Transient yet robust expression of proteins in the mouse liver via intravenous injection of lipid nanoparticle-encapsulated nucleoside-modified mRNA","volume":"11","author":"Everton","year":"2021","journal-title":"Bio Protoc"},{"key":"10.1016\/j.jgeb.2026.100717_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1233842","article-title":"Structure and function of molecular machines involved in deadenylation-dependent 5\u2032-3\u2032 mRNA degradation","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0475","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1039\/D4BM01290A","article-title":"Anionic polymer coating for enhanced delivery of Cas9 mRNA and sgRNA nanoplexes","volume":"13","author":"Chen","year":"2025","journal-title":"Biomater Sci"},{"issue":"4","key":"10.1016\/j.jgeb.2026.100717_bb0480","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in Technologies for Therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol Ther"},{"issue":"6478","key":"10.1016\/j.jgeb.2026.100717_bb0485","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science (1979)"},{"issue":"4","key":"10.1016\/j.jgeb.2026.100717_bb0490","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","article-title":"Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity","volume":"19","author":"Liu","year":"2024","journal-title":"Nat Nanotechnol"},{"issue":"11","key":"10.1016\/j.jgeb.2026.100717_bb0495","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.7150\/thno.113650","article-title":"Exosomes: innovative biomarkers leading the charge in non-invasive cancer diagnostics","volume":"15","author":"Li","year":"2025","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.jgeb.2026.100717_bb0500","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.jgeb.2026.100717_bb0505","article-title":"Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines Basel"},{"issue":"7","key":"10.1016\/j.jgeb.2026.100717_bb0510","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s11095-025-03890-8","article-title":"Mechanism of pH-sensitive amphiphilic endosomal escape of ionizable lipid nanoparticles for cytosolic nucleic acid delivery","volume":"42","author":"Lu","year":"2025","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0515","doi-asserted-by":"crossref","first-page":"344","DOI":"10.20517\/evcna.2024.19","article-title":"Endosomal escape mechanisms of extracellular vesicle-based drug carriers: lessons for lipid nanoparticle design","volume":"5","author":"Hagedorn","year":"2024","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"key":"10.1016\/j.jgeb.2026.100717_bb0520","series-title":"Generative AI: Current Trends and Applications","first-page":"427","article-title":"Generative AI in drug designing: Current state-of-the-art and perspectives","volume":"1177","author":"Ahmad","year":"2024"},{"issue":"28","key":"10.1016\/j.jgeb.2026.100717_bb0525","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/onc.2016.502","article-title":"Census and evaluation of p53 target genes","volume":"36","author":"Fischer","year":"2017","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.jgeb.2026.100717_bb0530","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ"},{"issue":"6","key":"10.1016\/j.jgeb.2026.100717_bb0535","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/cdd.2008.16","article-title":"In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute","volume":"15","author":"Michalak","year":"2008","journal-title":"Cell Death Differ"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0540","first-page":"256","article-title":"BH3-only proteins Noxa and Puma are key regulators of induced Apoptosis","volume":"12","author":"Roufayel","year":"2022","journal-title":"Life (Basel)"},{"issue":"5\u20136","key":"10.1016\/j.jgeb.2026.100717_bb0545","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10495-021-01667-z","article-title":"The role of P53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseases","volume":"26","author":"Li","year":"2021","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0550","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nrm1546","article-title":"p53: traffic cop at the crossroads of DNA repair and recombination","volume":"6","author":"Sengupta","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.jgeb.2026.100717_bb0555","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026070","article-title":"p53 in the DNA-damage-repair process","volume":"6","author":"Williams","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"10.1016\/j.jgeb.2026.100717_bb0560","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1158\/2159-8290.CD-13-0900","article-title":"Development of siRNA payloads to target KRAS -mutant Cancer","volume":"4","author":"Yuan","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jgeb.2026.100717_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.928399","article-title":"Opposing roles of wild-type and mutant p53 in the process of epithelial to mesenchymal transition","volume":"9","author":"Semenov","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jgeb.2026.100717_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.146175","article-title":"Evaluating the polypharmacological potential of cosmetic preservative Imidurea against lung Cancer-associated EGFR, CDK2, STAT3, BCL2, p53, and ABCB1 proteins","volume":"321","author":"Ahmad","year":"2025","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"10.1016\/j.jgeb.2026.100717_bb0575","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2174\/0115680096360059250131075456","article-title":"Groundbreaking mRNA lung Cancer vaccine trials: a new Dawn in Cancer treatment","volume":"25","author":"Hussain","year":"2025","journal-title":"CCDT"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0580","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-748","article-title":"Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive\u00ae) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer","volume":"14","author":"Sebastian","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jgeb.2026.100717_bb0585","article-title":"Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jgeb.2026.100717_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123047","article-title":"Targeted LNPs deliver IL-15 superagonists mRNA for precision cancer therapy","volume":"317","author":"Yu","year":"2025","journal-title":"Biomaterials"},{"issue":"523","key":"10.1016\/j.jgeb.2026.100717_bb0595","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1565","article-title":"Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53 -deficient cancers to mTOR inhibition","volume":"11","author":"Kong","year":"2019","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.jgeb.2026.100717_bb0600","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41587-024-02437-3","article-title":"Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR\u2013Cas9 ribonucleoprotein","volume":"43","author":"Chen","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"7662","key":"10.1016\/j.jgeb.2026.100717_bb0605","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"10427","key":"10.1016\/j.jgeb.2026.100717_bb0610","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0615","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40164-025-00625-8","article-title":"Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer","volume":"14","author":"Cai","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"13","key":"10.1016\/j.jgeb.2026.100717_bb0620","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/ijms23137213","article-title":"The therapeutic potential of the restoration of the p53 protein family members in the EGFR-mutated lung Cancer","volume":"23","author":"Fregni","year":"2022","journal-title":"IJMS"},{"issue":"8","key":"10.1016\/j.jgeb.2026.100717_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 loss promotes prostate Cancer resistance to a Spectrum of therapeutics and confers vulnerability to replication stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.jgeb.2026.100717_bb0630","article-title":"Lipid nanoparticle-based mRNA vaccines in cancers: current advances and future prospects","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jgeb.2026.100717_bb0635","article-title":"Lipid-mRNA nanoparticles landscape for cancer therapy","volume":"10","author":"Li","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"10.1016\/j.jgeb.2026.100717_bb0640","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1039\/D0BM01609H","article-title":"Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomater Sci"},{"issue":"6","key":"10.1016\/j.jgeb.2026.100717_bb0645","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1021\/acsnano.4c18636","article-title":"Ionizable lipids with optimized linkers enable lung-specific, lipid nanoparticle-mediated mRNA delivery for treatment of metastatic lung Tumors","volume":"19","author":"Somu Naidu","year":"2025","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.jgeb.2026.100717_bb0650","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat Nanotechnol"},{"issue":"709","key":"10.1016\/j.jgeb.2026.100717_bb0655","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq0603","article-title":"Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination","volume":"15","author":"Suberi","year":"2023","journal-title":"Sci Transl Med"},{"issue":"34","key":"10.1016\/j.jgeb.2026.100717_bb0660","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202505413","article-title":"Developing biomaterial-based mRNA delivery system for lung disease treatment","volume":"12","author":"Gu","year":"2025","journal-title":"Adv Sci"},{"issue":"10","key":"10.1016\/j.jgeb.2026.100717_bb0665","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41587-023-01679-x","article-title":"Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing","volume":"41","author":"Li","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.jgeb.2026.100717_bb0670","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/pharmaceutics17111502","article-title":"Nanoparticles used for the delivery of RNAi-based therapeutics","volume":"17","author":"Ren","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jgeb.2026.100717_bb0675","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1504124","article-title":"Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response","volume":"15","author":"Ning","year":"2025","journal-title":"Front Immunol"},{"issue":"21","key":"10.1016\/j.jgeb.2026.100717_bb0680","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202502624R","article-title":"Advances in inhaled nanoparticle drug delivery for pulmonary disease management","volume":"39","author":"Fan","year":"2025","journal-title":"FASEB J"},{"issue":"44","key":"10.1016\/j.jgeb.2026.100717_bb0685","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304966120","article-title":"Inhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection","volume":"120","author":"Tang","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0690","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12088-024-01304-8","article-title":"Mucus-penetrating PEGylated Nanoshuttle for enhanced drug delivery and healthcare applications","volume":"65","author":"Bain","year":"2025","journal-title":"Indian J Microbiol"},{"issue":"10","key":"10.1016\/j.jgeb.2026.100717_bb0695","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3390\/ph18101498","article-title":"Combined effect of size and charge on the interaction of nanoparticles with mucus-mimicking mucin hydrogels","volume":"18","author":"Porfiryeva","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jgeb.2026.100717_bb0700","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jcis.2022.11.059","article-title":"Insights into the mechanisms of interaction between inhalable lipid-polymer hybrid nanoparticles and pulmonary surfactant","volume":"633","author":"Xu","year":"2023","journal-title":"J Colloid Interface Sci"},{"issue":"4","key":"10.1016\/j.jgeb.2026.100717_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16040531","article-title":"Cell membrane-coated biomimetic nanoparticles in cancer treatment","volume":"16","author":"Zhang","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jgeb.2026.100717_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2026.01.070","article-title":"Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions","author":"Xu","year":"2026","journal-title":"J Adv Res"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0715","first-page":"pbae017","article-title":"Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology. Precis","volume":"7","author":"Jacob","year":"2024","journal-title":"Clin Med"},{"issue":"23","key":"10.1016\/j.jgeb.2026.100717_bb0720","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235589","article-title":"Progress and challenges of messenger RNA vaccines in the therapeutics of NSCLC","volume":"15","author":"Kiousi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jgeb.2026.100717_bb0725","article-title":"Emerging immunotherapies in lung cancer: the latest advances and the future of mRNA vaccines","volume":"13","author":"Ramos","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0730","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"j immunotherapy cancer"},{"issue":"16_suppl","key":"10.1016\/j.jgeb.2026.100717_bb0735","doi-asserted-by":"crossref","first-page":"9556","DOI":"10.1200\/JCO.2025.43.16_suppl.9556","article-title":"Phase I dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients (pts) with advanced solid tumors","volume":"43","author":"Piha-Paul","year":"2025","journal-title":"JCO"},{"issue":"108","key":"10.1016\/j.jgeb.2026.100717_bb0740","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ads1328","article-title":"An Il12 mRNA-LNP adjuvant enhances mRNA vaccine\u2013induced CD8 t cell responses","volume":"10","author":"Aunins","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jgeb.2026.100717_bb0745","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2017.09.012","article-title":"Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications","volume":"266","author":"Liu","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.jgeb.2026.100717_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115026","article-title":"Gene editing therapeutics based on mRNA delivery","volume":"200","author":"Popovitz","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.jgeb.2026.100717_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102737","article-title":"Unlocking mRNA-driven CRISPR-Cas9 gene therapy via optimizing mRNA and the delivery vectors","volume":"36","author":"Wang","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"10.1016\/j.jgeb.2026.100717_bb0760","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.jgeb.2026.100717_bb0765","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk8264","article-title":"Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality","volume":"10","author":"Liu","year":"2024","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0770","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.xphs.2019.10.003","article-title":"Immunogenicity of Cas9 protein","volume":"109","author":"Mehta","year":"2020","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.jgeb.2026.100717_bb0775","article-title":"CRISPR\/Cas9 systems: delivery technologies and biomedical applications","volume":"18","author":"Du","year":"2023","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.jgeb.2026.100717_bb0780","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","article-title":"Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population","volume":"10","author":"Simhadri","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0785","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/hum.2018.145","article-title":"Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response","volume":"30","author":"Foster","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.jgeb.2026.100717_bb0790","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13040844","article-title":"Novel mRNA-engineered fully human CAR-T cells targeting AXL in solid tumors","volume":"13","author":"Zou","year":"2025","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.jgeb.2026.100717_bb0795","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1089\/hum.2013.075","article-title":"Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced Leukemia","volume":"24","author":"Barrett","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"19","key":"10.1016\/j.jgeb.2026.100717_bb0800","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1039\/D1LC00219H","article-title":"mRNA-based CAR T-cells manufactured by miniaturized two-step electroporation produce selective cytotoxicity toward target cancer cells","volume":"21","author":"Jayasooriya","year":"2021","journal-title":"Lab Chip"},{"key":"10.1016\/j.jgeb.2026.100717_bb0805","doi-asserted-by":"crossref","unstructured":"Kumari K, Singh A, Chaudhary A, et al. Neoantigen identification and dendritic cell-based vaccines for lung cancer immunotherapy. Vaccines (Basel). 2024;12(5):498. doi:https:\/\/doi.org\/10.3390\/vaccines12050498.","DOI":"10.3390\/vaccines12050498"},{"issue":"7","key":"10.1016\/j.jgeb.2026.100717_bb0810","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1711-1","article-title":"Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jgeb.2026.100717_bb0815","article-title":"Reprogramming the immune microenvironment in lung cancer","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jgeb.2026.100717_bb0820","article-title":"The role of tumor-associated macrophages in lung cancer","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Immunol"},{"issue":"18","key":"10.1016\/j.jgeb.2026.100717_bb0825","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non\u2013small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0830","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55378-5","article-title":"Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment","volume":"16","author":"Alsaed","year":"2025","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jgeb.2026.100717_bb0835","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/cancers17050785","article-title":"KRAS mutations in Cancer: understanding Signaling pathways to immune regulation and the potential of immunotherapy","volume":"17","author":"Uniyal","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jgeb.2026.100717_bb0840","article-title":"Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0845","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.jgeb.2026.100717_bb0850","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jtho.2023.07.020","article-title":"STK11\/LKB1-deficient phenotype rather than mutation diminishes immunotherapy efficacy and represents STING\/type I interferon\/CD8+ T-cell dysfunction in NSCLC","volume":"18","author":"Li","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jgeb.2026.100717_bb0855","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.omtn.2023.07.020","article-title":"Intratumoral injection of IL-12-encoding mRNA targeted to CSF1R and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure","volume":"33","author":"Di Trani","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jgeb.2026.100717_bb0860","doi-asserted-by":"crossref","unstructured":"Gandhi L, Aufiero Ramirez K, Schwarzenberger P, et al. Phase 1\/2 study of mRNA vaccine therapy + durvalumab (durva) \u00b1 tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC). JCO 2018;36(15_suppl):TPS9107\u2013TPS9107. doi:https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.TPS9107.","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9107"},{"issue":"5","key":"10.1016\/j.jgeb.2026.100717_bb0865","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0870","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41467-026-68324-4","article-title":"Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial","volume":"17","author":"Huff","year":"2026","journal-title":"Nat Commun"},{"issue":"610","key":"10.1016\/j.jgeb.2026.100717_bb0875","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jgeb.2026.100717_bb0880","doi-asserted-by":"crossref","unstructured":"Lakshmipathi J, Santha S, Li M, et al. Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responses. In Review. Preprint posted online April 2025. doi:10.21203\/rs.3.rs-6024931\/v1.","DOI":"10.21203\/rs.3.rs-6024931\/v1"},{"key":"10.1016\/j.jgeb.2026.100717_bb0885","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1321318","article-title":"Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine","volume":"13","author":"Minnar","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.jgeb.2026.100717_bb0890","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0895","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000047114","article-title":"CRISPR\/CAS9-based gene editing in cancer therapy: a systematic review and meta-analysis on current status and future directions","volume":"105","author":"Rehman","year":"2026","journal-title":"Medicine"},{"issue":"7","key":"10.1016\/j.jgeb.2026.100717_bb0900","doi-asserted-by":"crossref","DOI":"10.3390\/cells13070568","article-title":"Preclinical advances in LNP-CRISPR therapeutics for solid tumor treatment","volume":"13","author":"Wang","year":"2024","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0905","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ymthe.2017.11.009","article-title":"mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma","volume":"26","author":"Wang","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jgeb.2026.100717_bb0910","series-title":"Regular and Young Investigator Award Abstracts","article-title":"578 anti-PD-1 therapy alters the generation and durability of de novo responses to vaccination in humans","author":"Burke","year":"2023"},{"key":"10.1016\/j.jgeb.2026.100717_bb0915","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251316988","article-title":"Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review","volume":"17","author":"Gomez-Randulfe","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.jgeb.2026.100717_bb0920","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007387","article-title":"Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment","volume":"11","author":"Donhauser","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jgeb.2026.100717_bb0925","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1074477","article-title":"Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jgeb.2026.100717_bb0930","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2024.1506627","article-title":"Editorial: precision oncology in the era of CRISPR-Cas9 technology","volume":"15","author":"Khalil","year":"2024","journal-title":"Front Genet"},{"issue":"9","key":"10.1016\/j.jgeb.2026.100717_bb0935","doi-asserted-by":"crossref","first-page":"8129","DOI":"10.3390\/ijms24098129","article-title":"Small-cell lung Cancer\u2014an update on targeted and immunotherapies","volume":"24","author":"McNamee","year":"2023","journal-title":"IJMS"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0940","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40164-025-00720-w","article-title":"Immunotherapy for small cell lung cancer: current challenges and prospects","volume":"14","author":"Zhong","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0945","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12957-022-02528-y","article-title":"Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC)","volume":"20","author":"Ding","year":"2022","journal-title":"World J Surg Oncol"},{"issue":"6","key":"10.1016\/j.jgeb.2026.100717_bb0950","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JOP.18.00204","article-title":"Managing patients with relapsed small-cell lung Cancer","volume":"14","author":"Gong","year":"2018","journal-title":"JOP"},{"key":"10.1016\/j.jgeb.2026.100717_bb0955","article-title":"Clinical impact of first-line chemotherapy combined with immune checkpoint inhibitors for limited-stage small cell lung cancer patients: a real-world propensity score matching study","volume":"17","author":"Hu","year":"2026","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jgeb.2026.100717_bb0960","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/pharmaceutics15020622","article-title":"mRNA-based therapeutics in Cancer treatment","volume":"15","author":"Sun","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0965","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/15476286.2024.2333123","article-title":"mRNA vaccine designs for optimal adjuvanticity and delivery","volume":"21","author":"Mochida","year":"2024","journal-title":"RNA Biol"},{"key":"10.1016\/j.jgeb.2026.100717_bb0970","first-page":"262","article-title":"Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis","volume":"33","author":"Lee","year":"2024","journal-title":"Bioact Mater"},{"issue":"3","key":"10.1016\/j.jgeb.2026.100717_bb0975","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1515\/ejnm-2014-0019","article-title":"Overcoming the pulmonary barrier: new insights to improve the efficiency of inhaled therapeutics","volume":"6","author":"Murgia","year":"2014","journal-title":"Eur J Nanomed"},{"issue":"8","key":"10.1016\/j.jgeb.2026.100717_bb0980","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/17425247.2018.1502267","article-title":"Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies","volume":"15","author":"Osman","year":"2018","journal-title":"Expert Opin Drug Deliv"},{"issue":"8","key":"10.1016\/j.jgeb.2026.100717_bb0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.xgen.2022.100165","article-title":"Spatial intra-tumor heterogeneity is associated with survival of lung adenocarcinoma patients","volume":"2","author":"Wu","year":"2022","journal-title":"Cell Genomics"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb0990","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010569","article-title":"Leveraging mRNA technology for antigen based immuno-oncology therapies","volume":"13","author":"Floudas","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"7957","key":"10.1016\/j.jgeb.2026.100717_bb0995","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","article-title":"The evolution of lung cancer and impact of subclonal selection in TRACERx","volume":"616","author":"Frankell","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb1000","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12967-024-06033-6","article-title":"mRNA vaccines in the context of cancer treatment: from concept to application","volume":"23","author":"Fu","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.jgeb.2026.100717_bb1005","article-title":"Identification of tumor antigens and immune subtypes in lung adenocarcinoma for mRNA vaccine development","volume":"10","author":"Xu","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"10.1016\/j.jgeb.2026.100717_bb1010","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13092187","article-title":"mRNA vaccines in modern immunotherapy for non-small cell lung cancer (NSCLC)\u2014a comprehensive literature review with focus on current clinical trials","volume":"13","author":"Kabut","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.jgeb.2026.100717_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122279","article-title":"Branched hydrophobic tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy","volume":"301","author":"Yan","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.jgeb.2026.100717_bb1020","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103928","article-title":"Loss of NLN suppresses lung cancer progression by inducing ferroptosis through downregulating m6A methylation of GPX4","volume":"88","author":"Liu","year":"2025","journal-title":"Redox Biol"},{"issue":"10","key":"10.1016\/j.jgeb.2026.100717_bb1025","doi-asserted-by":"crossref","DOI":"10.3390\/biom13101497","article-title":"Enabling mRNA therapeutics: current landscape and challenges in manufacturing","volume":"13","author":"Youssef","year":"2023","journal-title":"Biomolecules"},{"issue":"19","key":"10.1016\/j.jgeb.2026.100717_bb1030","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29194713","article-title":"Effective synthesis of mRNA during in vitro transcription with fewer impurities produced","volume":"29","author":"He","year":"2024","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.jgeb.2026.100717_bb1035","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1021\/acs.analchem.3c05539","article-title":"Comprehensive impurity profiling of mRNA: evaluating current technologies and advanced analytical techniques","volume":"96","author":"Camperi","year":"2024","journal-title":"Anal Chem"},{"issue":"11","key":"10.1016\/j.jgeb.2026.100717_bb1040","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17111452","article-title":"Practical pharmacokinetic\u2013pharmacodynamic models in oncology","volume":"17","author":"Guan","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jgeb.2026.100717_bb1045","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113896","article-title":"Clinical translation of immunomodulatory therapeutics","volume":"176","author":"Nash","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.jgeb.2026.100717_bb1050","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1038\/s41467-025-63726-2","article-title":"Protein corona formed on lipid nanoparticles compromises delivery efficiency of mRNA cargo","volume":"16","author":"Voke","year":"2025","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jgeb.2026.100717_bb1055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1208\/s12248-020-00464-x","article-title":"Protein Corona-enabled systemic delivery and targeting of nanoparticles","volume":"22","author":"Chen","year":"2020","journal-title":"AAPS J"},{"key":"10.1016\/j.jgeb.2026.100717_bb1060","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jconrel.2024.07.044","article-title":"Biofluid specific protein coronas affect lipid nanoparticle behavior in vitro","volume":"373","author":"Van Straten","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.jgeb.2026.100717_bb1065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fbioe.2020.00166","article-title":"Recent advances in understanding the protein Corona of nanoparticles and in the formulation of \u201cstealthy\u201d nanomaterials","volume":"8","author":"Rampado","year":"2020","journal-title":"Front Bioeng Biotechnol"}],"container-title":["Journal of Genetic Engineering and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687157X26000612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1687157X26000612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:58:38Z","timestamp":1789559918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1687157X26000612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":213,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1687157X26000612"],"URL":"https:\/\/doi.org\/10.1016\/j.jgeb.2026.100717","relation":{},"ISSN":["1687-157X"],"issn-type":[{"value":"1687-157X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Journal of Genetic Engineering and Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgeb.2026.100717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Academy of Scientific Research and Technology.","name":"copyright","label":"Copyright"}],"article-number":"100717"}}